RBC Capital analyst Shagun Singh Chadha maintains $Abbott Laboratories (ABT.US)$ with a buy rating, and adjusts the target price from $125 to $130.
According to TipRanks data, the analyst has a success rate of 48.0% and a total average return of 0.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
The firm's industry checks indicate that Q3 underlying utilization trends were favorable, notwithstanding the usual summer seasonality which generally leads to a sequential decrease in elective procedures. Additionally, investor sentiment towards MedTech stocks is optimistic as the earnings season approaches, with expectations that investors will likely keep gravitating towards successful and catalyst-driven companies as the year concludes.
Abbott is described as a 'large-cap diversified healthcare play' with a dual nature. One side boasts an appealing medical technology segment that accounts for 45% of its global sales totaling $42B, which is growing annually at a rate of 11%-13%. On the other side, its non-medical technology operations are experiencing low- to mid-single-digit growth influenced by legal concerns surrounding its pediatric nutrition business and diminishing COVID-19 diagnostics sales. As these challenges in the non-MedTech sector diminish, Abbott is anticipated to face more favorable comparisons in fiscal 2026, leading to an acceleration in sales growth to low-double-digits and an improvement in EBIT margins.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇资本市场分析师Shagun Singh Chadha维持$雅培 (ABT.US)$买入评级，并将目标价从125美元上调至130美元。
根据TipRanks数据显示，该分析师近一年总胜率为48.0%，总平均回报率为0.5%。
此外，综合报道，$雅培 (ABT.US)$近期主要分析师观点如下：
该公司的行业调查显示，第三季度的基础利用率趋势良好，尽管通常的夏季季节性变化通常会导致选修程序的连续减少。此外，随着财报季的临近，投资者对医疗科技股票的情绪持乐观态度，预计随着财报季的临近，投资者可能会继续倾向于成功且具有催化剂驱动的公司。
雅培被描述为具有双重性质的 “大盘多元化医疗保健公司”。一方拥有吸引人的医疗技术细分市场，占其全球销售额的45％，总额为420亿美元，每年增长11％-13％。另一方面，受围绕儿科营养业务的法律问题以及 COVID-19 诊断销售减少的影响，其非医疗技术业务正在经历低至中等个位数的增长。随着非医疗技术领域的这些挑战逐渐减少，预计雅培将在2026财年面临更有利的比较，这将导致销售增长加速至两位数的低位数，息税前利润率的提高。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
